TCS Unveils Agentic AI Platform to Revolutionize Global Drug Development

Tata Consultancy Services (TCS) has launched its new agentic AI platform, TCS ADD™ AgentHub, designed to transform drug development by streamlining clinical trials and pharmacovigilance workflows. The platform promises up to 40% efficiency gains in clinical data management, 30% faster study builds, and 30% cost savings in drug safety case processing.

Key Highlights of TCS ADD™ AgentHub

• Role-based AI agents: Each agent has defined responsibilities, oversight, and auditability, ensuring compliance in highly regulated pharma environments.
• Human + AI Operating Model: AI agents are embedded into enterprise workflows, while humans retain governance and decision-making authority.
• Efficiency gains: Up to 40% improvement in clinical data management activities.
• Automation benefits: Metadata-driven automation reduces clinical study build effort by 30%.
• Cost savings: End-to-end safety case processing costs cut by 30%.
• Quality control reduction: AI-powered safety agents reduce manual quality control effort by up to 50%.

Applications in Drug Development

• Clinical Trials: AI agents assist with study design, protocol digitization, clinical data review, and SDTM transformation.
• Pharmacovigilance: Agents handle individual case safety report intake, medical coding, literature analysis, and safety monitoring.
• Drug Safety: Automated workflows for adverse event reporting and compliance with regulatory standards.

Benefits for Pharma Companies

Feature	Impact
Efficiency Gains	40% faster clinical data management
Study Build Automation	30% reduction in effort
Cost Savings	30% lower safety case processing costs
Quality Control	50% less manual effort
Compliance	Built-in auditability and oversight

Challenges & Risks

• Regulatory compliance: Pharma firms must ensure AI outputs meet strict audit and governance standards.
• Integration hurdles: Legacy systems may slow adoption despite streamlined integration.
• Trust & scalability: Ensuring reliability and transparency of AI agents remains critical for industry-wide acceptance.

Strategic Outlook

TCS positions AgentHub as a scalable, audit-ready AI workforce that can accelerate drug development while improving patient safety. By embedding AI agents into pharma workflows, TCS aims to move towards autonomous enterprise functions, where humans and AI collaborate seamlessly.

Agilent and Veeda Lifesciences Launch Joint Analytical CoE to Accelerate GLP‑1 and Complex Biologics Development Services

Agilent Technologies, a global leader in analytical and laboratory solutions, today announced a strategic collaboration with Veeda Lifesciences to strengthen regulatory‑aligned analytical and bioanalytical workflows supporting biopharma development, as GLP‑1 and other complex therapeutic modalities continue to advance rapidly through global pipelines.

The collaboration brings together Agilent’s expertise in analytical workflow development with Veeda’s established bioanalytical, clinical research and regulatory capabilities, with the objective of enabling high‑quality, inspection‑ready analytical data across early development, clinical, and manufacturing stages. Together, the two organizations aim to support biopharma companies navigating increasingly complex regulatory and data expectations for next‑generation therapies.

Central to the collaboration is the establishment of a joint Center of Excellence (CoE) at Veeda’s biopharma facility in Bengaluru. Designed as a scalable analytics and regulatory‑readiness hub, the CoE will focus on the development and validation of end‑to‑end analytical workflows. The CoE will address the growing analytical demands associated with next‑generation therapies, including GLP‑1 based drugs - where sensitivity, throughput, and data integrity are critical to support regulatory confidence and program progression.

“As GLP‑1 and other complex therapies move rapidly through development, the need for robust, regulatory‑aligned analytics becomes increasingly critical,” said Nandakumar Kalathil, Country General Manager, Agilent India. “Through our collaboration with Veeda, we aim to support biopharma organizations with workflow‑driven analytical approaches that strengthen data quality, compliance, and confidence across the development lifecycle.”

“As Biopharma innovation accelerates across the region, the need for integrated, regulatory ready analytical ecosystems is becoming increasingly critical,” said Bharat Bhardwaj, Vice President and General Manager, Asia Pacific, Agilent Technologies. “This collaboration between Agilent and Veeda Lifesciences reflects our commitment to enabling customers with advanced, scalable solutions that support confident decision-making across the drug development lifecycle, while Asia Pacific’s role as a hub for high quality- globally relevant biopharma research.”

“Biopharma companies today require analytical capabilities that are inspection‑ready from the outset,” said Mr. Binoy Gardi, Group CEO and Managing Director, Veeda Lifesciences. “By collaborating with Agilent, we are strengthening our ability to deliver integrated, regulatory‑aligned analytical workflows that support faster decision‑making and smoother progression from early development through clinical and manufacturing stages.”

Dr. Sanjib Banerjee, Chief Operating Officer (COO), Biopharma at Veeda Lifesciences, added, “This expansion of our service portfolio establishes an advanced, technology‑driven platform for the structural analytical characterization of complex biologics—including peptides (GLP-1), monoclonal antibodies, antibody–drug conjugates (ADCs) and other therapeutic proteins. Built on Veeda’s established capabilities in in depth proteomics, glycoproteomic and process‑related impurities analysis, and leveraging Agilent’s high-end Mass Spectrometry, this creates an integrated, regulatory‑aligned analytical ecosystem under one roof.”

By combining Agilent’s high-performance mass spectrometry with Veeda’s integrated bioanalytical and clinical research infrastructure, the partnership aims to extend services to sponsors across an expanding range of next-generation modalities with consistent, inspection-ready datasets. The initiative underscores Agilent and Veeda’s commitment to expand India’s high-end biopharma research infrastructure, while reinforcing India’s role as a trusted destination for advanced, globally aligned biopharma development.

About Agilent Technologies

Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com.

About Veeda Lifesciences

Veeda Lifesciences is a leading independent contract research organization (CRO) offering comprehensive clinical, preclinical and bioanalytical services to support the development of innovative, biosimilar, and generic drugs. With state-of-the-art facilities in India and a strong focus on quality, and scientific excellence, Veeda partners with global pharmaceutical and biotech companies to accelerate product development and regulatory approvals.